Report Detail

This report "Congenital Heart Disease" provides an overview of the pipeline landscape for Congenital Heart Disease. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.

Report Overview:

This part of report provides detailed description of indication which enables the client to understand the landscape of the Congenital Heart Disease disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Congenital Heart Disease disease.

Pipeline Overview:

This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.

Drug Profile Overview:

The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.

Clinical Trial Overview:

This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.

Product Development Activity:

This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.

Company Overview:

Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial

Scope

• The report provides a competitive landscape of Congenital Heart Disease
• The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
• The report provides the list of companies which are the most active in the pipeline
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
• The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
• The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
• The report summarizes all the dormant and discontinued pipeline projects
• The report also provides latest news for the past one year

Reasons To Buy

• To identifying prominent players in the Congenital Heart Diseasetreatment landscape
• To determine the drivers; barriers and unmet need in the Congenital Heart Diseasetreatment space
• Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
• Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration